Current Trends on Glomerulosclerosis Regression

J Med Life. 2020 Apr-Jun;13(2):116-118. doi: 10.25122/jml-2020-0006.

Abstract

The role of the renin-angiotensin system in hypertension and end-organ damage has long been recognized. Angiotensin l converting enzyme inhibitors are superior to other antihypertensive agents in protecting the kidney against progressive deterioration, even in normotensive persons. Likewise, angiotensin II type 1 receptor antagonists improve or even reverse glomerulosclerosis in rat animal models. These findings suggest that Angiotensin II has nonhemodynamic effects in progressive renal disease. The renin-angiotensin system is now recognized to be linked to the induction of plasminogen activator-inhibitor-1, possibly via the AT4 receptor, thus promoting both thrombosis and fibrosis. Interactions of the renin-angiotensin system with aldosterone and bradykinin may impact both blood pressure and tissue injury. The beneficial effect on renal fibrosis of inhibiting the renin-angiotensin system likely reflects the central role that angiotensin has in regulating renal function and structure by its various actions. This article explores the renin-angiotensin-aldosterone system with plasminogen activator-inhibitor-1 interaction and the potential significance of these interactions in the pathogenesis of progressive renal disease and remodeling of renal sclerosis.

Keywords: Renin-angiotensin system; aldosterone; glomerulosclerosis; plasminogen activator-inhibitor-1; renal fibrosis.

Publication types

  • Review

MeSH terms

  • Aging / pathology
  • Aldosterone / metabolism
  • Angiotensins / metabolism
  • Animals
  • Humans
  • Kidney Diseases / pathology*
  • Remission Induction
  • Renin-Angiotensin System

Substances

  • Angiotensins
  • Aldosterone